Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3473-501. doi: 10.1007/s00213-016-4396-5. Epub 2016 Aug 28. Review.

2.

The effects of chronic alcohol self-administration on serotonin-1A receptor binding in nonhuman primates.

Hillmer AT, Wooten DW, Tudorascu DL, Barnhart TE, Ahlers EO, Resch LM, Larson JA, Converse AK, Moore CF, Schneider ML, Christian BT.

Drug Alcohol Depend. 2014 Nov 1;144:119-26. doi: 10.1016/j.drugalcdep.2014.08.015. Epub 2014 Aug 29.

3.

Subanesthetic doses of ketamine transiently decrease serotonin transporter activity: a PET study in conscious monkeys.

Yamamoto S, Ohba H, Nishiyama S, Harada N, Kakiuchi T, Tsukada H, Domino EF.

Neuropsychopharmacology. 2013 Dec;38(13):2666-74. doi: 10.1038/npp.2013.176. Epub 2013 Jul 24.

4.

Positron emission tomography quantification of serotonin transporter in suicide attempters with major depressive disorder.

Miller JM, Hesselgrave N, Ogden RT, Sullivan GM, Oquendo MA, Mann JJ, Parsey RV.

Biol Psychiatry. 2013 Aug 15;74(4):287-95. doi: 10.1016/j.biopsych.2013.01.024. Epub 2013 Mar 1.

5.

Interaction between serotonin transporter and dopamine D2/D3 receptor radioligand measures is associated with harm avoidant symptoms in anorexia and bulimia nervosa.

Bailer UF, Frank GK, Price JC, Meltzer CC, Becker C, Mathis CA, Wagner A, Barbarich-Marsteller NC, Bloss CS, Putnam K, Schork NJ, Gamst A, Kaye WH.

Psychiatry Res. 2013 Feb 28;211(2):160-8. doi: 10.1016/j.pscychresns.2012.06.010. Epub 2012 Nov 13.

6.
7.

The 5-HT(2A) receptor and serotonin transporter in Asperger's disorder: A PET study with [¹¹C]MDL 100907 and [¹¹C]DASB.

Girgis RR, Slifstein M, Xu X, Frankle WG, Anagnostou E, Wasserman S, Pepa L, Kolevzon A, Abi-Dargham A, Laruelle M, Hollander E.

Psychiatry Res. 2011 Dec 30;194(3):230-234. doi: 10.1016/j.pscychresns.2011.04.007. Epub 2011 Nov 12.

8.

5-HT radioligands for human brain imaging with PET and SPECT.

Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM.

Med Res Rev. 2013 Jan;33(1):54-111. doi: 10.1002/med.20245. Epub 2011 Jun 14. Review.

9.

Differential effects of cocaine and MDMA self-administration on cortical serotonin transporter availability in monkeys.

Gould RW, Gage HD, Banks ML, Blaylock BL, Czoty PW, Nader MA.

Neuropharmacology. 2011 Jul-Aug;61(1-2):245-51. doi: 10.1016/j.neuropharm.2011.04.007. Epub 2011 Apr 17.

10.

Metabolism and disposition of 3,4-methylenedioxymethamphetamine ("ecstasy") in baboons after oral administration: comparison with humans reveals marked differences.

Mueller M, Goodwin AK, Ator NA, McCann UD, Ricaurte GA.

J Pharmacol Exp Ther. 2011 Jul;338(1):310-7. doi: 10.1124/jpet.111.180612. Epub 2011 Apr 14.

11.

Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB.

Laje G, Cannon DM, Allen AS, Klaver JM, Peck SA, Liu X, Manji HK, Drevets WC, McMahon FJ.

Int J Neuropsychopharmacol. 2010 Jul;13(6):715-24. doi: 10.1017/S1461145709991027. Epub 2010 Jan 5.

12.

Imaging serotonergic transmission with [11C]DASB-PET in depressed and non-depressed patients infected with HIV.

Hammoud DA, Endres CJ, Hammond E, Uzuner O, Brown A, Nath A, Kaplin AI, Pomper MG.

Neuroimage. 2010 Feb 1;49(3):2588-95. doi: 10.1016/j.neuroimage.2009.10.037. Epub 2009 Oct 21.

13.

Synthesis, radiosynthesis, and biological evaluation of fluorine-18-labeled 2beta-carbo(fluoroalkoxy)-3beta-(3'-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography.

Stehouwer JS, Jarkas N, Zeng F, Voll RJ, Williams L, Camp VM, Malveaux EJ, Votaw JR, Howell L, Owens MJ, Goodman MM.

J Med Chem. 2008 Dec 25;51(24):7788-99. doi: 10.1021/jm800781a.

14.

Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Psychopharmacology (Berl). 2008 Oct;200(3):439-50. doi: 10.1007/s00213-008-1218-4. Epub 2008 Jul 27.

15.

Mechanisms of dopaminergic and serotonergic neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET.

Wong DF, Brasić JR, Singer HS, Schretlen DJ, Kuwabara H, Zhou Y, Nandi A, Maris MA, Alexander M, Ye W, Rousset O, Kumar A, Szabo Z, Gjedde A, Grace AA.

Neuropsychopharmacology. 2008 May;33(6):1239-51. Epub 2007 Nov 7.

16.

Effects of cocaine and MDMA self-administration on serotonin transporter availability in monkeys.

Banks ML, Czoty PW, Gage HD, Bounds MC, Garg PK, Garg S, Nader MA.

Neuropsychopharmacology. 2008 Jan;33(2):219-25. Epub 2007 Apr 18.

17.

Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Neuropsychopharmacology. 2005 Sep;30(9):1741-50.

Supplemental Content

Support Center